Join us for the ACC Delaware Chapter Meeting: ACC by the Sea for engaging live education sessions from local, regional, and national experts with Q&A real-time. The educational meeting includes topics of cardio obstetrics, lipids, amyloid, etc., and a chapter update from our Governor Dr. Vinay Hosmane. Participation in this event will earn CME/CNE/and MOC. We look forward to seeing you (IN-PERSON) September 25 - 26, 2026!

For more Information and Register: Delaware ACC By the Sea: 2026 Chapter Meeting

Download the Brochure: Brochure

Delaware Chapter of the American College of Cardiology


Our purpose is to contribute to the prevention of cardiovascular diseases, to ensure optimal quality of care for individuals with such diseases, and to foster the highest professional ethical standards. Please let us know what information you want to see here. Feel free to contact us with your ideas, needs and comments.

ACC Live Courses

For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings

RSS feed: Latest in Cardiology from ACC.org Latest in Cardiology from ACC.org

  • HFSA 2026: ATTRibute-CM Analysis; LINK-HF2 Results; More
    New science presented at HFSA 2026 and simultaneously published in JACC: Heart Failure spans several evolving areas in heart failure (HF), from ATTR-CM biomarkers and measures of physical function to predictors of adverse outcomes in transplant recipients to artificial intelligence (AI) wearables enhancing discharge care following HF hospitalization.
  • ACC-Supported Radiation Safety Coalition Seeks Clinician Input
    The ACC and the ALARA+ Coalition are seeking input from cardiovascular clinicians and health care facility administrators to help better understand the real-world impacts of occupational radiation exposure and inform future workplace safety efforts.
  • ACCEL Lite: TRANQUILITY: IL-6, An Important Mediator of CVD
    In this episode, Dipti Itchhaporia MD, MACC and Deepak L. Bhatt, MD, MPH, MBA, FACC discuss TRANQUILITY: Efficacy of monthly and quarterly dosing of pacibekitug (IL-6 ligand mAb) targeting inflammation in CKD with high cardiovascular risk.
  • CKM Syndrome: Insights From and Comparison of Recent Guidelines
    The 2026 ACC/AHA/Multisociety Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome provides an expanded framework for assessing and managing interconnected metabolic risk factors...
  • FDA Update: Agency Warns of Transcatheter MV Delivery System Issue
    The U.S. Food and Drug Administration (FDA) has issued an Early Alert, warning that Edwards Lifesciences is recommending certain delivery systems used for the SAPIEN M3 transcatheter mitral valve (MV) replacement be removed from use.